Hemex Health, Inc. is a U.S.-based medical diagnostics company focused on point-of-care testing for hemoglobin disorders and malaria. The company’s Gazelle platform is designed to identify and quantify hemoglobin variants—such as HbA, HbS, and HbF—to support screening, diagnosis, and treatment monitoring for conditions including sickle cell disease.
Gazelle is a portable, battery-operated system that combines microchip electrophoresis with integrated analysis software to deliver results in settings with limited laboratory infrastructure. Hemex Health serves clinics, hospitals, screening programs, and blood centers, with an emphasis on improving access to timely testing in underserved regions.
